Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
37.91
-0.70 (-1.81%)
May 30, 2025, 3:20 PM - Market open
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $744.86M in the quarter ending March 31, 2025, with 80.15% growth. This brings the company's revenue in the last twelve months to $2.23B, up 59.15% year-over-year. In the year 2024, Sarepta Therapeutics had annual revenue of $1.90B with 52.97% growth.
Revenue (ttm)
$2.23B
Revenue Growth
+59.15%
P/S Ratio
1.66
Revenue / Employee
$1,627,821
Employees
1,372
Market Cap
3.73B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
SRPT News
- 9 days ago - Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy - Business Wire
- 14 days ago - Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment - Business Wire
- 14 days ago - Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 - Business Wire
- 17 days ago - Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy - Business Wire
- 21 days ago - Top 3 Health Care Stocks That Are Preparing To Pump This Quarter - Benzinga
- 21 days ago - Sarepta Therapeutics to Present at the BofA Securities Health Care Conference - Business Wire
- 23 days ago - Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating - Seeking Alpha
- 23 days ago - Sarepta Therapeutics Stock Sinks On Gloomy Forecast, Analysts Expect Demand To Pick Up - Benzinga